The first FDA-approved treatment for
chorea associated with Huntington’s disease1
Home | About HD Chorea
Find a Physician
Decrease text size Text Size Increase text size

Make a Move Against Huntington’s
Disease (HD) Chorea

Chorea is the most striking physical manifestation of
Huntington's disease (HD)5

Q:What percentage of HD patients are affected by chorea?

A:Chorea affects about 90% of patients with HD at some stage in their illness3

Chorea may often be the first presenting symptom in HD6

  • Minimal at outset, affecting only the face or the distal portions of limbs
  • Later may become generalized and interfere with the patient's voluntary movements3

The hallmark symptoms of Huntington's disease

The hallmark presentation of Huntington’s disease includes motor, cognitive, and psychiatric symptoms.2 The signs of chorea can be recognized in all stages of Huntington’s disease (HD).3

Clinical assessment of chorea severity4

Chorea is typically assessed as part of the Unified Huntington’s Disease Rating Scale (UHDRS) – a valid and reliable research tool developed by the Huntington Study Group (HSG).4

Xenazine® (tetrabenazine) is indicated to treat chorea associated with HD; it does not treat cognitive or psychiatric symptoms.

UHDRS Total Chorea Score Chart

Sources:

  1. "FDA Approves First Drug for Treatment of Chorea in Huntington's Disease", FDA News Release, August 15, 2008: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116936.htm. Updated April 15, 2013. Accessed August 17, 2015.
  2. Rosenblatt A, Ranen NG, Nance MA, Paulsen JS. A Physician’s Guide to the Management of Huntington’s Disease. 2nd ed. 1999. http://hdsarockymountain.org/wp-content/uploads/2009/04/physicians_guide.pdf. Accessed February 15, 2010.
  3. Haddad MS, Cummings JL. Huntington’s disease. Neuropsychiatry of the basal ganglia. Psychiatry Clinics of North America 1997;20:791-807
  4. Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord. 1996; 11:136-142.
  5. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009; 9:62.
  6. Kirkwood SC, Su JL, Conneally PM, Foroud T. Progression of symptoms in the early and middle stages of Huntington's disease. Arch Neurol. 2001;58:273-278.

XENAZINE® (tetrabenazine) Tablets

Indications and Usage:

XENAZINE is indicated for the treatment of chorea associated with Huntington’s disease.

Important Safety Information:

WARNING: DEPRESSION AND SUICIDALITY
See full prescribing information for complete boxed warning.

  • Increases the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease.
  • Balance risks of depression and suicidality with the clinical need for control of chorea when considering the use of XENAZINE.
  • Monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior.
  • Inform patients, caregivers, and families of the risk of depression and suicidality and instruct to report behaviors of concern promptly to the treating physician.
  • Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation.
  • XENAZINE is contraindicated in patients who are actively suicidal, and in patients with untreated or inadequately treated depression.
  • XENAZINE is also contraindicated in patients who have impaired hepatic function or are taking monoamine oxidase inhibitors (MAOIs) or reserpine. XENAZINE should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI. At least 20 days should elapse after stopping reserpine before starting XENAZINE.
  • Prescribers should periodically re-evaluate the need for XENAZINE in their patients by assessing the beneficial effect on chorea and possible adverse effects, including worsening mood, cognition, rigidity, and functional capacity. XENAZINE should be titrated slowly over several weeks for a dose that is appropriate for each patient.
  • Before a dose greater than 50 mg/day is administered, the patient's CYP2D6 metabolizer status should be determined. Do not exceed 50 mg/day or 25 mg/dose if XENAZINE is administered with a strong CYP2D6 inhibitor.
  • XENAZINE therapy should be re-titrated if there is a treatment interruption of greater than 5 days, or a treatment interruption occurring due to a change in the patient's medical condition or concomitant medications.
  • A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with XENAZINE. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria, rhabdomyolysis, and acute renal failure. The management of NMS should include immediate discontinuation of XENAZINE and other drugs not essential to concurrent therapy.
  • XENAZINE can also cause other serious side effects, including: akathisia, restlessness, agitation, parkinsonism, and sedation/somnolence. These side effects may require a dose reduction or discontinuation of XENAZINE. Monitoring of vital signs on standing should be considered in patients who are vulnerable to hypotension. Dysphagia has also been reported with use of XENAZINE; some cases of dysphagia were associated with aspiration pneumonia.
  • QT prolongation–related arrhythmias have been reported with use of XENAZINE. XENAZINE should not be used in combination with drugs known to prolong QTc (which in certain circumstances can lead to torsades de pointes and/or sudden death), in patients with congenital long QT syndrome, or in patients with a history of cardiac arrhythmias. A potentially irreversible syndrome of involuntary, dyskinetic movements called tardive dyskinesia (TD) may develop in patients treated with neuroleptic drugs. If signs and symptoms of TD appear in a patient treated with XENAZINE, drug discontinuation should be considered. The risk of parkinsonism, NMS, and akathisia may be increased by concomitant use of XENAZINE and dopamine antagonists or antipsychotics.
  • XENAZINE elevates serum prolactin concentrations. XENAZINE may induce sedation/somnolence which may impair the ability to drive or operate dangerous machinery. Alcohol or other sedating drugs can worsen sedation/somnolence.
  • Some adverse events, such as depression, fatigue, insomnia, sedation/somnolence, parkinsonism, and akathisia, may be dose-dependent. If the adverse effect does not resolve or decrease, consideration should be given to lowering or discontinuing XENAZINE. The most commonly reported adverse events with XENAZINE compared to placebo were sedation/somnolence (31% vs 3%), fatigue (22% vs 13%), insomnia (22% vs 0%), depression (19% vs 0%), akathisia (19% vs 0%), anxiety (15% vs 3%), and nausea (13% vs 7%).

For more information, please see the full Prescribing Information, including Boxed Warning, the Medication Guide or go to www.XENAZINEusa.com.

Xenazine is a registered trademark of Valeant International Bermuda or its affiliates.

©2017 Lundbeck, Deerfield, IL 60015. All rights reserved.

The product information provided in this site is intended only for residents of the U.S. The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider.

TBZ-B-00184(2)